<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8368">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835926</url>
  </required_header>
  <id_info>
    <org_study_id>GRC16</org_study_id>
    <nct_id>NCT00835926</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination</brief_title>
  <official_title>Safety and Immunogenicity of Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® 2003/2004</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the safety during days 0 to 21 following injection of the 2003-2004 formulation
      of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and
      subjects aged ≥ 60 years.

      To describe the immune response at 21 days following injection of the 2003-2004 formulation
      of the inactivated, split-virion influenza vaccine Fluzone®, in subjects aged 18-59 years
      and subjects aged ≥ 60 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety will be assessed throughout the trial period. Using antigens provided by Aventis
      Pasteur Inc., pre- and post-vaccination serum antibody titers for each of the three vaccine
      strains will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-Vaccination With Fluzone®</measure>
    <time_frame>Days 0 to 3 Post-vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Solicited injection site reactions: Erythema, bruising, induration, and Pain at injection site.
Solicited systemic reaction: Fever (temperature), chills, rash, headache, cough, runny nose, nausea, vomiting, diarrhea, malaise, myalgia, and arthralgia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibodies Before and After Vaccination With Fluzone®</measure>
    <time_frame>Day 0 and Day 21 Post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a ≥ 4-Fold Rise in Serum Hemagglutination Inhibition Antibody Titers Post-Vaccination With Fluzone®</measure>
    <time_frame>Day 21 Post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serum Hemagglutination Inhibition Antibody Titers ≥ 40 Post-Vaccination With Fluzone®</measure>
    <time_frame>Day 21 Post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Fluzone® Vaccine Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 18 to 59 years at enrollment - Fluzone® Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone® Vaccine Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 60 years and older at enrollment - Fluzone® Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza virus vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Fluzone® Vaccine Group 1</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza virus vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Fluzone® Vaccine Group 2</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Age of 18 years or greater.

          -  Ambulatory.

          -  In reasonably good health as assessed by the investigator.

          -  Available for duration of the study (21 days + 2d).

          -  Willing and able to meet protocol requirements.

          -  Willing and able to give informed consent.

        Exclusion Criteria :

          -  Self-reported allergy to egg proteins, chicken proteins, or one of the constituents
             of the vaccine, such as thimerosal or formaldehyde.

          -  An acute illness with or without fever (temperature &gt;100.4°F) in the 72 hours
             preceding enrollment in the trial.

          -  Clinically significant findings in vital signs (including temperature &gt;100.4°F) or
             review of systems.

          -  Self-reported history of severe adverse event to any influenza vaccine.

          -  Vaccination against influenza in the 6 months preceding enrollment in the study.

          -  Any vaccination in the 14 days preceding enrollment in the study or scheduled between
             Visit 1 and Visit 3.

          -  Participation in any other experimental drug or vaccine trial within the 30 days
             preceding enrollment into the study.

          -  Immunosuppressive therapy including long-term (&gt; 2 weeks) systemic corticosteroids or
             cancer therapy within the past 3 months or ongoing.

          -  Receipt of blood or blood products within the 3 months preceding enrollment in the
             study.

          -  Diabetes

          -  Any condition which, in the opinion of the investigator, would pose a health risk to
             the subject or interfere with the evaluation of the vaccine (e.g., existing severe
             chronic illness such as pulmonary disorders, cardiovascular disorders, chronic blood
             disorders, etc.).

          -  Person deprived of freedom by an administrative or court order (having legal or
             medical guardian).

          -  For women of childbearing age, a positive urine pregnancy test, breast feeding, or
             not using a medically approved and reliable form of contraception (oral
             contraceptives or double barrier method) for the duration of the trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 12, 2016</lastchanged_date>
  <firstreceived_date>January 27, 2009</firstreceived_date>
  <firstreceived_results_date>September 23, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Fluzone®</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled and treated from 25 July 2003 to 26 August 2003 at 1 US site.</recruitment_details>
      <pre_assignment_details>A total of 121 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluzone® Vaccine Group 1</title>
          <description>Participants were 18 to 59 years old at enrollment in the study</description>
        </group>
        <group group_id="P2">
          <title>Fluzone® Vaccine Group 2</title>
          <description>Participants were 60 years or older at enrollment in the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluzone® Vaccine Group 1</title>
          <description>Participants were 18 to 59 years old at enrollment in the study</description>
        </group>
        <group group_id="B2">
          <title>Fluzone® Vaccine Group 2</title>
          <description>Participants were 60 years or older at enrollment in the study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="121"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="65"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="55"/>
                <measurement group_id="B3" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Age Continuous</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40.7" spread="10.43"/>
                <measurement group_id="B2" value="73.7" spread="6.16"/>
                <measurement group_id="B3" value="57.1" spread="18.65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="87"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="121"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-Vaccination With Fluzone®</title>
        <description>Solicited injection site reactions: Erythema, bruising, induration, and Pain at injection site.
Solicited systemic reaction: Fever (temperature), chills, rash, headache, cough, runny nose, nausea, vomiting, diarrhea, malaise, myalgia, and arthralgia</description>
        <time_frame>Days 0 to 3 Post-vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety analysis was on all enrolled and vaccinated participants, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® Vaccine Group 1</title>
            <description>Participants were 18 to 59 years old at enrollment in the study</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group 2</title>
            <description>Participants were 60 years or older at enrollment in the study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-Vaccination With Fluzone®</title>
            <description>Solicited injection site reactions: Erythema, bruising, induration, and Pain at injection site.
Solicited systemic reaction: Fever (temperature), chills, rash, headache, cough, runny nose, nausea, vomiting, diarrhea, malaise, myalgia, and arthralgia</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Erythema (&gt; 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Induration (&gt; 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Bruising</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Bruising (&gt; 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain (Decreased ability to move arm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Chills (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Rash (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Cough</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Cough (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Runny Nose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Runny Nose (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Nausea (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Vomiting (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Diarrhea (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Malaise (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibodies Before and After Vaccination With Fluzone®</title>
        <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay.</description>
        <time_frame>Day 0 and Day 21 Post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Geometric mean titers were analyzed in the per-protocol immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® Vaccine Group 1</title>
            <description>Participants were 18 to 59 years old at enrollment in the study</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group 2</title>
            <description>Participants were 60 years or older at enrollment in the study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibodies Before and After Vaccination With Fluzone®</title>
            <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Panama/2007/99 Pre-Dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.6" lower_limit="22.6" upper_limit="38.7"/>
                  <measurement group_id="O2" value="20.4" lower_limit="15.9" upper_limit="26.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Panama/2007/99 Post-Dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67.1" lower_limit="50.7" upper_limit="88.7"/>
                  <measurement group_id="O2" value="37.5" lower_limit="29.5" upper_limit="47.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/New Caledonia/20/99 Pre-Dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.3" lower_limit="13.6" upper_limit="24.7"/>
                  <measurement group_id="O2" value="9.5" lower_limit="7.7" upper_limit="11.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/New Caledonia/20/99 Post-Dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.3" lower_limit="34.3" upper_limit="62.5"/>
                  <measurement group_id="O2" value="15.1" lower_limit="12.1" upper_limit="18.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Hong Kong/1434/2002 Pre-Dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.7" lower_limit="8.6" upper_limit="13.3"/>
                  <measurement group_id="O2" value="8.2" lower_limit="6.8" upper_limit="9.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Hong Kong/1434/2002 Post-Dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.8" lower_limit="22.1" upper_limit="34.9"/>
                  <measurement group_id="O2" value="15.9" lower_limit="12.6" upper_limit="20.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a ≥ 4-Fold Rise in Serum Hemagglutination Inhibition Antibody Titers Post-Vaccination With Fluzone®</title>
        <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay.</description>
        <time_frame>Day 21 Post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The vaccine antibody fold rise analysis was in the per-protocol immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® Vaccine Group 1</title>
            <description>Participants were 18 to 59 years old at enrollment in the study</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group 2</title>
            <description>Participants were 60 years or older at enrollment in the study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With a ≥ 4-Fold Rise in Serum Hemagglutination Inhibition Antibody Titers Post-Vaccination With Fluzone®</title>
            <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay.</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Panama/2007/99</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/New Caledonia/20/99</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Hong Kong/1434/2002</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serum Hemagglutination Inhibition Antibody Titers ≥ 40 Post-Vaccination With Fluzone®</title>
        <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay</description>
        <time_frame>Day 21 Post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Fluzone® antibody titers were analyzed in the per-protocol immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone® Vaccine Group 1</title>
            <description>Participants were 18 to 59 years old at enrollment in the study</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Vaccine Group 2</title>
            <description>Participants were 60 years or older at enrollment in the study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Serum Hemagglutination Inhibition Antibody Titers ≥ 40 Post-Vaccination With Fluzone®</title>
            <description>Hemagglutination inhibition antibodies is a measure of the serum antibody to the influenza virus in the vaccine as determined by the hemagglutinin inhibition (HAI) assay</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Panama/2007/99</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/New Caledonia/20/99</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Hong Kong/1434/2002</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluzone® Vaccine Group 1</title>
          <description>Participants were 18 to 59 years old at enrollment in the study</description>
        </group>
        <group group_id="E2">
          <title>Fluzone® Vaccine Group 2</title>
          <description>Participants were 60 years or older at enrollment in the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
